These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 8821842)
1. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products. Miyata T; Iida Y; Ueda Y; Shinzato T; Seo H; Monnier VM; Maeda K; Wada Y Kidney Int; 1996 Feb; 49(2):538-50. PubMed ID: 8821842 [TBL] [Abstract][Full Text] [Related]
2. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. Miyata T; Inagi R; Iida Y; Sato M; Yamada N; Oda O; Maeda K; Seo H J Clin Invest; 1994 Feb; 93(2):521-8. PubMed ID: 8113390 [TBL] [Abstract][Full Text] [Related]
3. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Miyata T; Taneda S; Kawai R; Ueda Y; Horiuchi S; Hara M; Maeda K; Monnier VM Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2353-8. PubMed ID: 8637877 [TBL] [Abstract][Full Text] [Related]
4. Glycation of human beta 2-microglobulin in patients with hemodialysis-associated amyloidosis: identification of the glycated sites. Miyata T; Inagi R; Wada Y; Ueda Y; Iida Y; Takahashi M; Taniguchi N; Maeda K Biochemistry; 1994 Oct; 33(40):12215-21. PubMed ID: 7918443 [TBL] [Abstract][Full Text] [Related]
5. Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis. Iida Y; Miyata T; Inagi R; Sugiyama S; Maeda K Biochem Biophys Res Commun; 1994 Jun; 201(3):1235-41. PubMed ID: 8024566 [TBL] [Abstract][Full Text] [Related]
6. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931 [TBL] [Abstract][Full Text] [Related]
7. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. Miyata T; Oda O; Inagi R; Iida Y; Araki N; Yamada N; Horiuchi S; Taniguchi N; Maeda K; Kinoshita T J Clin Invest; 1993 Sep; 92(3):1243-52. PubMed ID: 8376584 [TBL] [Abstract][Full Text] [Related]
8. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467 [TBL] [Abstract][Full Text] [Related]
9. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733 [TBL] [Abstract][Full Text] [Related]
10. New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction. Miyata T; Maeda K Nephrol Dial Transplant; 1996; 11 Suppl 2():140-3. PubMed ID: 8804015 [No Abstract] [Full Text] [Related]
12. Beta2-microglobulin and renal bone disease. Wada T; Miyata T; Sakai H; Kurokawa K Perit Dial Int; 1999; 19 Suppl 2():S413-6. PubMed ID: 10406556 [TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of advanced glycation end-products in renal failure. Miyata T; Iida Y; Horie K; Cai Z; Sugiyama S; Maeda K Nephrol Dial Transplant; 1996; 11 Suppl 5():27-30. PubMed ID: 9044303 [TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Matsuo K; Ikizler TA; Hoover RL; Nakamoto M; Yasunaga C; Pupim LB; Hakim RM Kidney Int; 2000 Feb; 57(2):697-708. PubMed ID: 10652049 [TBL] [Abstract][Full Text] [Related]
15. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure. Miyata T Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608 [TBL] [Abstract][Full Text] [Related]
16. Modification of beta 2-microglobulin with D-glucose or 3-deoxyglucosone inhibits A beta 2M amyloid fibril extension in vitro. Hashimoto N; Naiki H; Gejyo F Amyloid; 1999 Dec; 6(4):256-64. PubMed ID: 10611946 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Niwa T; Miyazaki S; Katsuzaki T; Tatemichi N; Takei Y; Miyazaki T; Morita T; Hirasawa Y Kidney Int; 1995 Sep; 48(3):771-8. PubMed ID: 7474663 [TBL] [Abstract][Full Text] [Related]
18. Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits. Argilés A; García-García M; Derancourt J; Mourad G; Demaille JG Kidney Int; 1995 Nov; 48(5):1397-405. PubMed ID: 8544395 [TBL] [Abstract][Full Text] [Related]
19. Implication of the glycoxidation and lipoxidation reactions in the pathogenesis of dialysis-related amyloidosis (Review). Sugiyama S; Miyata T; Inagi R; Kurokawa K Int J Mol Med; 1998 Nov; 2(5):561-5. PubMed ID: 9858652 [TBL] [Abstract][Full Text] [Related]
20. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis. Miyata T; Inagi R; Kurokawa K Miner Electrolyte Metab; 1999; 25(1-2):114-7. PubMed ID: 10207272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]